1. Home
  2. CTGO vs TRDA Comparison

CTGO vs TRDA Comparison

Compare CTGO & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Contango ORE Inc.

CTGO

Contango ORE Inc.

HOLD

Current Price

$24.17

Market Cap

365.7M

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$10.22

Market Cap

386.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTGO
TRDA
Founded
2009
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
365.7M
386.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CTGO
TRDA
Price
$24.17
$10.22
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$24.50
AVG Volume (30 Days)
98.4K
298.8K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$61,520,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.85
$4.93
52 Week High
$26.88
$21.79

Technical Indicators

Market Signals
Indicator
CTGO
TRDA
Relative Strength Index (RSI) 60.11 78.19
Support Level $20.64 $8.17
Resistance Level $23.18 $10.75
Average True Range (ATR) 1.29 0.67
MACD 0.26 0.16
Stochastic Oscillator 93.86 87.24

Price Performance

Historical Comparison
CTGO
TRDA

About CTGO Contango ORE Inc.

Contango Ore Inc operates in the United States. The company is engaged in the exploration of gold, silver, and copper ores in the State of Alaska. The company's focus is the exploration of a mineral lease with the Native Village of Tetlin whose governmental entity is the Tetlin Tribal Council for the exploration of minerals near Tok, Alaska. It has formed a joint venture to advance exploration of the Tetlin Property, which is prospective for gold and associated minerals. The Peak Gold JV Property is located in the Tetlin Hills and Mentasta Mountains of eastern interior Alaska. Its exploration projects are Lucky Shot, Johnson Tract, Eagle, Hona, Shamrock, and Triple Z.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: